Etodolac (Etova-MR FORTE) (Etodolac (Etova-MR FORTE)) is a nonsteroidal anti-inflammatory drug (NSAID). Etodolac (Etova-MR FORTE) works by reducing hormones that cause inflammation and pain in the body.
Etodolac (Etova-MR FORTE) is used to treat mild to moderate pain, osteoarthritis, or rheumatoid arthritis.
Etodolac (Etova-MR FORTE) may also be used for purposes not listed in this medication guide.
Etodolac (Etova-MR FORTE) indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
Carefully consider the potential benefits and risks of Etodolac (Etova-MR FORTE) and other treatment options before deciding to use Etodolac (Etova-MR FORTE). Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
Etodolac (Etova-MR FORTE) are indicated:
*
For relief of signs and symptoms of juvenile arthritis
*
For relief of the signs and symptoms of rheumatoid arthritis
*
For relief of the signs and symptoms of osteoarthritis
How should I use Etodolac (Etova-MR FORTE)?
Use Etodolac (Etova-MR FORTE) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Etodolac (Etova-MR FORTE) comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Etodolac (Etova-MR FORTE) refilled.
Take Etodolac (Etova-MR FORTE) by mouth with or without food. It may be taken with food if it upsets your stomach. Taking it with food may not lower the risk of stomach or bowel problems (eg, bleeding, ulcers). Talk with your doctor or pharmacist if you have persistent stomach upset.
Swallow Etodolac (Etova-MR FORTE) whole. Do not break, crush, or chew before swallowing.
Take Etodolac (Etova-MR FORTE) with a full glass of water (8 oz/240 mL) as directed by your doctor.
If you miss a dose of Etodolac (Etova-MR FORTE) and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose. Go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about the proper use of Etodolac (Etova-MR FORTE).
Uses of Etodolac (Etova-MR FORTE) in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored
Etodolac (Etova-MR FORTE) is used to relieve painful conditions of the bone, joints and soft tissues such as inflammatory arthritis (rheumatoid arthritis) and advanced osteoarthritis.
Etodolac (Etova-MR FORTE) description
Etodolac (Etova-MR FORTE) is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
Etodolac (Etova-MR FORTE) dosage
Etodolac (Etova-MR FORTE) Dosage
Generic name: Etodolac (Etova-MR FORTE)
Dosage form: Capsules and Tablets
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Carefully consider the potential benefits and risks of Etodolac (Etova-MR FORTE) and other treatment options before deciding to use Etodolac (Etova-MR FORTE). Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
After observing the response to initial therapy with Etodolac (Etova-MR FORTE), the dose and frequency should be adjusted to suit an individual patient's needs. As with other NSAIDs, the lowest dose and longest dosing interval should be sought for each patient. Therefore, after observing the response to initial therapy with Etodolac (Etova-MR FORTE), the dose and frequency should be adjusted to suit an individual patient's needs.
Dosage adjustment of Etodolac (Etova-MR FORTE) is generally not required in patients with mild to moderate renal impairment. Etodolac (Etova-MR FORTE) should be used with caution in such patients, because, as with other NSAIDs, it may further decrease renal function in some patients with impaired renal function.
Analgesia
The recommended total daily dose of Etodolac (Etova-MR FORTE) for acute pain is up to 1000 mg, given as 200-400 mg every 6 to 8 hours. Doses of Etodolac (Etova-MR FORTE) greater than 1000 mg/day have not been adequately evaluated in well-controlled clinical trials.
Osteoarthritis and Rheumatoid Arthritis
The recommended starting dose of Etodolac (Etova-MR FORTE) for the management of the signs and symptoms of osteoarthritis or rheumatoid arthritis is: 300 mg b.i.d., t.i.d., or 400 mg b.i.d., or 500 mg b.i.d. A lower dose of 600 mg/day may suffice for long-term administration. Physicians should be aware that doses above 1000 mg/day have not been adequately evaluated in well-controlled clinical trials.
In chronic conditions, a therapeutic response to therapy with Etodolac (Etova-MR FORTE) is sometimes seen within one week of therapy, but most often is observed by two weeks. After a satisfactory response has been achieved, the patient's dose should be reviewed and adjusted as required.
More about Etodolac (Etova-MR FORTE) (Etodolac (Etova-MR FORTE))
Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
Antacids
The concomitant administration of antacids has no apparent effect on the extent of absorption of Etodolac (Etova-MR FORTE). However, antacids can decrease the peak concentration reached by 15% to 20% but have no detectable effect on the time-to-peak.
Aspirin
When Etodolac (Etova-MR FORTE) is administered with aspirin, its protein binding is reduced, although the clearance of free Etodolac (Etova-MR FORTE) is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of Etodolac (Etova-MR FORTE) and aspirin is not generally recommended because of the potential of increased adverse effects.
Cyclosporine, Digoxin, Methotrexate
Etodolac (Etova-MR FORTE), like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increase toxicity. Nephrotoxicity associated with cyclosporine may also be enhanced. Patients receiving these drugs who are given Etodolac (Etova-MR FORTE), or any other NSAID, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs. NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.
Diuretics
Etodolac (Etova-MR FORTE) has no apparent pharmacokinetic interaction when administered with furosemide or hydrochlorothiazide. Nevertheless, clinical studies, as well as post marketing observations have shown that Etodolac (Etova-MR FORTE) can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for sings of renal failure, as well as to assure diuretic efficacy.
Glyburide
Etodolac (Etova-MR FORTE) has no apparent pharmacokinetic interaction when administered with glyburide.
Lithium
NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
Phenylbutazone
Phenylbutazone causes increase (by about 80%) in the free fraction of Etodolac (Etova-MR FORTE). Although in vivo studies have not been done to see if Etodolac (Etova-MR FORTE) clearance is changed by coadministration of phylbutazone, it is not recommended that they be coadministered.
Phenytoin
Etodolac (Etova-MR FORTE) has no apparent pharmacokinetic interaction when administered with phenytoin.
Warfarin
The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone. Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Etodolac (Etova-MR FORTE) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin. There was no significant difference in the pharmacodynamic effect of warfarin administered alone and warfarin administered with Etodolac (Etova-MR FORTE) as measured by prothrombin time. Thus, concomitant therapy with warfarin and Etodolac (Etova-MR FORTE) should not require dosage adjustment of either drug. However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in Etodolac (Etova-MR FORTE)-treated patients receiving concomitant warfarin therapy.
Drug/Laboratory Test Interactions
The urine of patients who take Etodolac (Etova-MR FORTE) can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of Etodolac (Etova-MR FORTE). Diagnostic dip-stick methodology, used to detect ketone bodies in urine, has resulted in false-positive findings in some patients treated with Etodolac (Etova-MR FORTE). Generally, this phenomenon has not been associated with other clinically significant events. No dose relationship has been observed.
Etodolac (Etova-MR FORTE) treatment is associated with a small decrease in serum uric acid levels. In clinical trials, mean decreases of 1 to 2 mg/dL were observed in arthritic patients receiving Etodolac (Etova-MR FORTE) (600 mg to 1000 mg/day) after 4 weeks of therapy. These levels then remained stable for up to 1 year of therapy.
A total of 1552 patients were exposed to Etodolac (Etova-MR FORTE) in controlled clinical studies of at least 4 weeks in length and using daily doses in the range of 400 to 1200 mg. In the tabulations below, adverse event rates are generally categorized based on the incidence of events in the first 30 days of treatment with Etodolac (Etova-MR FORTE). As with other NSAIDs, the cumulative adverse event rates may increase significantly over time with extended therapy.
In patients taking NSAIDs, including Etodolac (Etova-MR FORTE), the most frequently reported adverse experiences occurring in approximately 1 to 10% of patients are: gastrointestinal experiences including:
*
Adverse events that were observed in < 1% of patients in the first 30 days of treatment with Etodolac (Etova-MR FORTE) in clinical trials.
abdominal pain
constipation
diarrhea
dyspepsia
flatulence
GI ulcers (gastric/duodenal)*
gross bleeding/perforation*
nausea
vomiting
other events including:
abnormal renal function*
anemia*
asthenia
dizziness
edema*
elevated liver enzymes*
headaches
hypertension
increased bleeding time*
infection
pharyngitis
pruritus
rashes
rhinitis
tinnitus*
Additional NSAID Adverse Experiences Reported Occasionally with NSAIDs or Etodolac (Etova-MR FORTE) Include
Body as a whole - allergic reaction, anaphylactic/anaphylactoid reactions (including shock), chills, fever, sepsis
Cardiovascular system - congestive heart failure, flushing, palpitations, tachycardia, syncope, vasculitis (including necrotizing and allergic)
This medicine can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use Etodolac (Etova-MR FORTE). Do not use this medicine just before or after having heart bypass surgery (also called coronary artery bypass graft, or CABG).
Seek emergency medical help if you have symptoms of heart or circulation problems, such as chest pain, weakness, shortness of breath, slurred speech, or problems with vision or balance.
This medicine can also increase your risk of serious effects on the stomach or intestines, including bleeding or perforation (forming of a hole). These conditions can be fatal and gastrointestinal effects can occur without warning at any time while you are taking Etodolac (Etova-MR FORTE). Older adults may have an even greater risk of these serious gastrointestinal side effects.
Call your doctor at once if you have symptoms of bleeding in your stomach or intestines. This includes black, bloody, or tarry stools, or coughing up blood or vomit that looks like coffee grounds.
Do not use any other over-the-counter cold, allergy, or pain medication without first asking your doctor or pharmacist. Many medicines available over the counter contain aspirin or other medicines similar to Etodolac (Etova-MR FORTE) (such as ibuprofen, ketoprofen, or naproxen). If you take certain products together you may accidentally take too much of this type of medication. Read the label of any other medicine you are using to see if it contains aspirin, ibuprofen, ketoprofen, or naproxen.
Do not drink alcohol while taking Etodolac (Etova-MR FORTE). Alcohol can increase the risk of stomach bleeding caused by Etodolac (Etova-MR FORTE).
Avoid exposure to sunlight or artificial UV rays (sunlamps or tanning beds). Etodolac (Etova-MR FORTE) can make your skin more sensitive to sunlight and sunburn may result.
Thiocolchicoside (Etova-MR FORTE) indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
Bromazepam is an intermediate-acting tranquiliser, prescribed for the treatment of moderate to severe anxiety and panic disorders and for the short-term treatment of insomnia. Unlike the benzodiazepine alprazolam it does not possess any antidepressant qualities.
In low doses it diminishes anxiety and tension. In higher doses the sedative and muscle-relaxant properties appear.
Uses of Thiocolchicoside (Etova-MR FORTE) in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
Thiocolchicoside (Etova-MR FORTE) is used (as an additive treatment) for relieving painful stiffness or constriction in various diseases of the muscles, nerves, spine and the joints.
Thiocolchicoside (Etova-MR FORTE) description
Thiocolchicoside (Etova-MR FORTE) is a muscle relaxant with anti-inflammatory and analgesic effects. It acts as a competitive GABAA receptor antagonist and also glycine receptor antagonist with similar potency and nicotinic acetylcholine receptors to a much lesser extent. It has powerful convulsant activity and should not be used in seizure-prone individuals.
Thiocolchicoside (Etova-MR FORTE) dosage
Oral
Muscle spasms
Adult: Initially, 16 mg daily.
Intramuscular
Muscle spasms
Adult: Up to 8 mg daily.
Thiocolchicoside (Etova-MR FORTE) interactions
LEXOTAN undergoes hepatic microsomal oxidation via the cytochrome P450 liver enzymes.
Therefore, caution should be taken in patients taking medicines that inhibit the P450 liver enzymes (e.g. azole antifungals, macrolide antibiotics, HIV protease inhibitors, calcium channel blocking agents).
LEXOTAN undergoes oxidative metabolism and, consequently, may interact with disulfiram or cimetidine resulting in increased plasma levels of LEXOTAN. Patients should be observed closely for evidence of enhanced benzodiazepine response during concomitant treatment with either disulfiram or cimetidine; some patients may require a reduction in benzodiazepine dosage.
The benzodiazepines, including LEXOTAN, produce additive CNS depressant effects when coadministered with other medications which themselves produce CNS depression e.g. barbiturates, alcohol, sedatives, antidepressants, hypnotics, anxiolytics, phenothiazines and other antipsychotics,
skeletal muscle relaxants, antihistamines, narcotic analgesics and anaesthetics.
Alcohol should be avoided in patients receiving LEXOTAN.
In the case of narcotic analgesics enhancement of euphoria may also occur, leading to an increase in psychic drug dependence.
The anticholinergic effects of atropine and similar medicines, antihistamines and antidepressants may be potentiated.
Interactions have been reported between some benzodiazepines and anticonvulsants, with changes in the serum concentration of the benzodiazepine or anticonvulsant. It is recommended that patients be observed for altered responses when benzodiazepines and anticonvulsants are prescribed together and that serum level monitoring of the anticonvulsant be performed more frequently.
Interference with Clinical, Laboratory or Other Tests:
Minor EEG changes, usually low voltage fast activity, of no known clinical significance, has been
reported with benzodiazepine administration.
Thiocolchicoside (Etova-MR FORTE) side effects
Photosensitivity reactions,Thiocolchicoside (Etova-MR FORTE) Tablets and capsules may cause irritation of the digestive system. Therefore, your doctor Thiocolchicoside (Etova-MR FORTE) tablets / capsules during your use of gastric protective drugs may tell you to use. Follow your doctor’s instructions.
If diarrhea occurs In such a situation should reduce your dosage. Thiocolchicoside (Etova-MR FORTE) rest, physical therapy and other measures, including pain relief is only one part of the complete treatment program.
Avoid drinking alcohol. Alkol Thiocolchicoside (Etova-MR FORTE) alcohol may increase some side effects.
DailyMed. "ETODOLAC: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Etova-MR FORTE are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Etova-MR FORTE. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
Consumer reviews
There are no reviews yet. Be the first to write one!
